Q1'22 | Q1'21 | Q4'21 | ||||
Revenue (mil) | $ 755 | $ 782 | $885 | |||
GAAP EPS | $ 0.92 | $ 1.09 | $1.26 | |||
Non-GAAP EPS | $ 0.98 | $ 1.11 | $1.37 |
“We delivered first quarter results ahead of the midpoint of our January outlook as we successfully resolved some short-term supply constraints at Universal Robots,” said Teradyne President and CEO
Guidance for the second quarter of 2022 is revenue of
Webcast
A conference call to discuss the first quarter results, along with management's business outlook, will follow at
Non-GAAP Results
In addition to disclosing results that are determined in accordance with GAAP, Teradyne also discloses non-GAAP results of operations that exclude certain income items and charges. These results are provided as a complement to results provided in accordance with GAAP. Non-GAAP income from operations and non-GAAP net income exclude acquired intangible assets amortization, restructuring and other, pension actuarial gains and losses, losses on convertible debt conversions, non-cash convertible debt interest, discrete income tax adjustments, and includes the related tax impact on non-GAAP adjustments. GAAP requires that these items be included in determining income from operations and net income. Non-GAAP income from operations, non-GAAP net income, non-GAAP income from operations as a percentage of revenue, non-GAAP net income as a percentage of revenue, and non-GAAP net income per share are non-GAAP performance measures presented to provide meaningful supplemental information regarding Teradyne’s baseline performance before gains, losses or other charges that may not be indicative of Teradyne’s current core business or future outlook. These non-GAAP performance measures are used to make operational decisions, to determine employee compensation, to forecast future operational results, and for comparison with Teradyne’s business plan, historical operating results and the operating results of Teradyne’s competitors. Non-GAAP diluted shares include the impact of Teradyne’s call option on its shares. Management believes each of these non-GAAP performance measures provides useful supplemental information for investors, allowing greater transparency to the information used by management in its operational decision making and in the review of Teradyne’s financial and operational performance, as well as facilitating meaningful comparisons of Teradyne’s results in the current period compared with those in prior and future periods. A reconciliation of each available GAAP to non-GAAP financial measure discussed in this press release is contained in the attached exhibits and on the Teradyne website at www.teradyne.com by clicking on “Investor Relations” and then selecting “Financials” and the “GAAP to Non-GAAP Reconciliation” link. The non-GAAP performance measures discussed in this press release may not be comparable to similarly titled measures used by other companies. The presentation of non-GAAP measures is not meant to be considered in isolation, as a substitute for, or superior to, financial measures or information provided in accordance with GAAP.
About Teradyne
Teradyne (NASDAQ:TER) brings high-quality innovations such as smart devices, life-saving medical equipment and data storage systems to market, faster. Its advanced test solutions for semiconductors, electronic systems, wireless devices and more ensure that products perform as they were designed. Its Industrial Automation offerings include collaborative and mobile robots that help manufacturers of all sizes improve productivity and lower costs. In 2021, Teradyne had revenue of $3.7 billion and today employs over 6,000 people worldwide. For more information, visit teradyne.com. Teradyne® is a registered trademark of Teradyne, Inc. in the
Safe Harbor Statement
This release contains forward-looking statements regarding Teradyne’s future business prospects, the impact of the global pandemic of the novel strain of the coronavirus (COVID-19), results of operations, market conditions, earnings per share, the impact of supply chain conditions on the business, customer sales expectations, the payment of a quarterly dividend, the repurchase of Teradyne common stock pursuant to a share repurchase program, sanctions against
On
On
In response to the regulations issued by the
Following Russia’s invasion of
COVID-19 has resulted in authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, government vaccination mandates and other government regulations. These measures have impacted and may further impact Teradyne’s workforce and operations, the operations of its customers, and those of its contract manufacturers and suppliers. As Teradyne implements measures to comply with additional regulations, the Company may experience increased compliance costs, increased risk of non-compliance and increased risk of employee attrition.
The COVID-19 pandemic has adversely impacted the Company’s results of operations, including increased costs company-wide and constraints within the Company’s supply chain. The Company cannot accurately estimate the amount of the impact on Teradyne’s 2022 financial results and to its future financial results. The COVID-19 outbreak has significantly increased economic and demand uncertainty in Teradyne’s markets. This uncertainty resulted in a significant decrease in demand for certain Teradyne products and could continue to impact demand for an uncertain period of time. The spread of COVID-19 has caused Teradyne to modify its business practices (including employee travel, employees working remotely, and cancellation of in person participation in meetings, events and conferences) and the Company may take further actions as may be required by government authorities or that it determines are in the best interests of its employees, customers, contract manufacturers and suppliers. There is uncertainty that such measures will be sufficient to mitigate the risks posed by the virus, and Teradyne’s ability to perform critical functions could be impacted. The degree to which COVID-19 continues to impact Teradyne’s results will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and continued spread of the virus, its severity, the actions to contain the virus or the availability and impact of vaccines in countries where the Company does business, and how quickly and to what extent normal economic and operating conditions can resume.
Important factors that could cause actual results, the 2024 earnings model, earnings per share, use of cash, dividend payments, repurchases of common stock, or payment of the senior convertible notes to differ materially from those presently expected include: conditions affecting the markets in which Teradyne operates; decreased or delayed product demand from one or more significant customers; development, delivery and acceptance of new products; the ability to grow the Industrial Automation business; increased research and development spending; deterioration of Teradyne’s financial condition; the continued impact of the COVID-19 pandemic and related government responses on the market and demand for Teradyne’s products, on its contract manufacturers and supply chain, and on its workforce; the impact of the global semiconductor supply shortage on our supply chain and contract manufacturers; the consummation and success of any mergers or acquisitions; demand for products by the Company’s largest customers; unexpected cash needs; insufficient cash flow to make required payments and pay the principal amount on the senior convertible notes; the business judgment of the board of directors that a declaration of a dividend or the repurchase of common stock is not in the Company’s best interests; additional
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
(In thousands, except per share amounts) | ||||||||||||||||
Quarter Ended | ||||||||||||||||
2022 | 2021 | 2021 | ||||||||||||||
Net revenues | $ | 755,370 | $ | 885,047 | $ | 781,606 | ||||||||||
Cost of revenues (exclusive of acquired intangible assets amortization shown separately below) (1) | 300,437 | 357,998 | 319,988 | |||||||||||||
Gross profit | 454,933 | 527,049 | 461,618 | |||||||||||||
Operating expenses: | ||||||||||||||||
Selling and administrative | 140,185 | 142,747 | 129,797 | |||||||||||||
Engineering and development | 108,116 | 109,965 | 100,402 | |||||||||||||
Acquired intangible assets amortization | 5,063 | 5,163 | 5,536 | |||||||||||||
Restructuring and other (2) | 15,714 | 12,738 | (7,130 | ) | ||||||||||||
Operating expenses | 269,078 | 270,613 | 228,605 | |||||||||||||
Income from operations | 185,855 | 256,436 | 233,013 | |||||||||||||
Interest and other expense (3) | 5,496 | 1,256 | 9,020 | |||||||||||||
Income before income taxes | 180,359 | 255,180 | 223,993 | |||||||||||||
Income tax provision | 18,431 | 31,140 | 18,481 | |||||||||||||
Net income | $ | 161,928 | $ | 224,040 | $ | 205,512 | ||||||||||
Net income per common share: | ||||||||||||||||
Basic | $ | 1.00 | $ | 1.38 | $ | 1.23 | ||||||||||
Diluted | $ | 0.92 | $ | 1.26 | $ | 1.09 | ||||||||||
Weighted average common shares - basic | 162,048 | 162,769 | 166,491 | |||||||||||||
Weighted average common shares - diluted (4) | 175,565 | 178,020 | 187,740 | |||||||||||||
Cash dividend declared per common share | $ | 0.11 | $ | 0.10 | $ | 0.10 | ||||||||||
(1 | ) | Cost of revenues includes: | Quarter Ended | |||||||||||||
2022 | 2021 | 2021 | ||||||||||||||
Provision for excess and obsolete inventory | $ | 1,590 | $ | 3,700 | $ | 2,827 | ||||||||||
Sale of previously written down inventory | (262 | ) | (434 | ) | (790 | ) | ||||||||||
$ | 1,328 | $ | 3,266 | $ | 2,037 | |||||||||||
(2 | ) | Restructuring and other consists of: | Quarter Ended | |||||||||||||
2022 | 2021 | 2021 | ||||||||||||||
Litigation settlement | $ | 14,700 | $ | 12,000 | $ | - | ||||||||||
Employee severance | 551 | 284 | 188 | |||||||||||||
Acquisition related expenses and compensation | (201 | ) | 174 | (237 | ) | |||||||||||
Contingent consideration fair value adjustment | - | - | (7,227 | ) | ||||||||||||
Other | 664 | 280 | 146 | |||||||||||||
$ | 15,714 | $ | 12,738 | $ | (7,130 | ) | ||||||||||
(3 | ) | Interest and other includes: | Quarter Ended | |||||||||||||
2022 | 2021 | 2021 | ||||||||||||||
Loss on convertible debt conversions | $ | - | $ | 3,431 | $ | 4,069 | ||||||||||
Non-cash convertible debt interest | - | 1,166 | 3,581 | |||||||||||||
Pension actuarial losses | - | (1,590 | ) | - | ||||||||||||
$ | - | $ | 3,007 | $ | 7,650 | |||||||||||
(4 | ) | Under GAAP, when calculating diluted earnings per share, convertible debt must be assumed to have converted if the effect on EPS would be dilutive. Diluted shares assume the conversion of the convertible debt as the effect would be dilutive. Accordingly, for the quarters ended | ||||||||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) | ||||||||||||||||
2022 | 2021 | |||||||||||||||
Assets | ||||||||||||||||
Cash and cash equivalents | $ | 794,603 | $ | 1,122,199 | ||||||||||||
Marketable securities | 282,016 | 244,231 | ||||||||||||||
Accounts receivable, net | 546,881 | 550,749 | ||||||||||||||
Inventories, net | 259,341 | 243,330 | ||||||||||||||
Prepayments | 479,414 | 406,266 | ||||||||||||||
Other current assets | 12,127 | 9,452 | ||||||||||||||
Total current assets | 2,374,382 | 2,576,227 | ||||||||||||||
Property, plant and equipment, net | 399,485 | 387,240 | ||||||||||||||
Operating lease right-of-use assets, net | 67,718 | 68,807 | ||||||||||||||
Marketable securities | 126,130 | 133,858 | ||||||||||||||
Deferred tax assets | 113,556 | 102,428 | ||||||||||||||
Retirement plans assets | 14,669 | 15,110 | ||||||||||||||
Other assets | 23,480 | 24,096 | ||||||||||||||
Acquired intangible assets, net | 69,846 | 75,635 | ||||||||||||||
419,888 | 426,024 | |||||||||||||||
Total assets | $ | 3,609,154 | $ | 3,809,425 | ||||||||||||
Liabilities | ||||||||||||||||
Accounts payable | $ | 156,493 | $ | 153,133 | ||||||||||||
Accrued employees' compensation and withholdings | 139,287 | 253,667 | ||||||||||||||
Deferred revenue and customer advances | 155,761 | 146,185 | ||||||||||||||
Other accrued liabilities | 118,252 | 124,187 | ||||||||||||||
Operating lease liabilities | 18,523 | 19,977 | ||||||||||||||
Income taxes payable | 103,386 | 88,789 | ||||||||||||||
Current debt | 20,497 | 19,182 | ||||||||||||||
Total current liabilities | 712,199 | 805,120 | ||||||||||||||
Retirement plans liabilities | 151,697 | 151,141 | ||||||||||||||
Long-term deferred revenue and customer advances | 51,698 | 54,921 | ||||||||||||||
Long-term other accrued liabilities | 15,748 | 15,497 | ||||||||||||||
Deferred tax liabilities | 4,927 | 6,327 | ||||||||||||||
Long-term operating lease liabilities | 55,934 | 56,178 | ||||||||||||||
Long-term income taxes payable | 67,041 | 67,041 | ||||||||||||||
Debt | 75,378 | 89,244 | ||||||||||||||
Total liabilities | 1,134,622 | 1,245,469 | ||||||||||||||
Mezzanine equity | - | 1,512 | ||||||||||||||
Shareholders' equity | 2,474,532 | 2,562,444 | ||||||||||||||
Total liabilities, convertible common shares and shareholders’ equity | $ | 3,609,154 | $ | 3,809,425 | ||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) | ||||||||||||||||
Quarter Ended | ||||||||||||||||
2022 | 2021 | |||||||||||||||
Cash flows from operating activities: | ||||||||||||||||
Net income | $ | 161,928 | $ | 205,512 | ||||||||||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||||||
Depreciation | 22,503 | 23,910 | ||||||||||||||
Stock-based compensation | 12,894 | 12,232 | ||||||||||||||
Amortization | 5,233 | 9,822 | ||||||||||||||
Deferred taxes | 11,288 | (1,057 | ) | |||||||||||||
Losses (gains) on investments | 2,001 | (2,491 | ) | |||||||||||||
Provision for excess and obsolete inventory | 1,590 | 2,285 | ||||||||||||||
Loss on convertible debt conversions | - | 4,069 | ||||||||||||||
Contingent consideration fair value adjustment | - | (7,227 | ) | |||||||||||||
Other | 177 | 200 | ||||||||||||||
Changes in operating assets and liabilities: | ||||||||||||||||
Accounts receivable | 208 | (87,512 | ) | |||||||||||||
Inventories | (9,480 | ) | (35,870 | ) | ||||||||||||
Prepayments and other assets | (74,305 | ) | (86,131 | ) | ||||||||||||
Accounts payable and other liabilities | (124,382 | ) | (10,571 | ) | ||||||||||||
Deferred revenue and customer advances | 6,747 | 7,952 | ||||||||||||||
Retirement plans contributions | (1,329 | ) | (1,925 | ) | ||||||||||||
Income taxes | (7,611 | ) | 4,941 | |||||||||||||
Net cash provided by operating activities | 7,462 | 38,139 | ||||||||||||||
Cash flows from investing activities: | ||||||||||||||||
Purchases of property, plant and equipment | (43,999 | ) | (39,250 | ) | ||||||||||||
Purchases of marketable securities | (165,977 | ) | (211,604 | ) | ||||||||||||
Proceeds from maturities of marketable securities | 96,682 | 194,228 | ||||||||||||||
Proceeds from sales of marketable securities | 30,581 | 61,293 | ||||||||||||||
Net cash (used for) provided by investing activities | (82,713 | ) | 4,667 | |||||||||||||
Cash flows from financing activities: | ||||||||||||||||
Issuance of common stock under stock purchase and stock option plans | 16,475 | 17,144 | ||||||||||||||
Repurchase of common stock | (201,465 | ) | (45,188 | ) | ||||||||||||
Payments related to net settlement of employee stock compensation awards | (31,048 | ) | (30,675 | ) | ||||||||||||
Payments of convertible debt principal | (20,694 | ) | (51,275 | ) | ||||||||||||
Dividend payments | (17,895 | ) | (16,667 | ) | ||||||||||||
Net cash used for financing activities | (254,627 | ) | (126,661 | ) | ||||||||||||
Effects of exchange rate changes on cash and cash equivalents | 2,282 | 883 | ||||||||||||||
Decrease in cash and cash equivalents | (327,596 | ) | (82,972 | ) | ||||||||||||
Cash and cash equivalents at beginning of period | 1,122,199 | 914,121 | ||||||||||||||
Cash and cash equivalents at end of period | $ | 794,603 | $ | 831,149 | ||||||||||||
GAAP to Non-GAAP Earnings Reconciliation | ||||||||||||||||||||||||||||||||||||||||||||||||
(In millions, except per share amounts) | ||||||||||||||||||||||||||||||||||||||||||||||||
Quarter Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
2022 | % of Net Revenues | 2021 | % of Net Revenues | 2021 | % of Net Revenues | |||||||||||||||||||||||||||||||||||||||||||
Net revenues | $ | 755.4 | $ | 885.0 | $ | 781.6 | ||||||||||||||||||||||||||||||||||||||||||
Gross profit GAAP and non-GAAP | $ | 454.9 | 60.2 | % | $ | 527.0 | 59.5 | % | $ | 461.6 | 59.1 | % | ||||||||||||||||||||||||||||||||||||
Income from operations - GAAP | $ | 185.9 | 24.6 | % | $ | 256.4 | 29.0 | % | $ | 233.0 | 29.8 | % | ||||||||||||||||||||||||||||||||||||
Restructuring and other (1) | 15.7 | 2.1 | % | 12.7 | 1.4 | % | (7.1 | ) | -0.9 | % | ||||||||||||||||||||||||||||||||||||||
Acquired intangible assets amortization | 5.1 | 0.7 | % | 5.2 | 0.6 | % | 5.5 | 0.7 | % | |||||||||||||||||||||||||||||||||||||||
Income from operations - non-GAAP | $ | 206.7 | 27.4 | % | $ | 274.3 | 31.0 | % | $ | 231.4 | 29.6 | % | ||||||||||||||||||||||||||||||||||||
Net Income per Common Share | Net Income per Common Share | Net Income per Common Share | ||||||||||||||||||||||||||||||||||||||||||||||
2022 | % of Net Revenues | Basic | Diluted | % of Net Revenues | Basic | Diluted | 2021 | % of Net Revenues | Basic | Diluted | ||||||||||||||||||||||||||||||||||||||
Net income - GAAP | $ | 161.9 | 21.4 | % | $ | 1.00 | $ | 0.92 | $ | 224.0 | 25.3 | % | $ | 1.38 | $ | 1.26 | $ | 205.5 | 26.3 | % | $ | 1.23 | $ | 1.09 | ||||||||||||||||||||||||
Restructuring and other (1) | 15.7 | 2.1 | % | 0.10 | 0.09 | 12.7 | 1.4 | % | 0.08 | 0.07 | (7.1 | ) | -0.9 | % | (0.04 | ) | (0.04 | ) | ||||||||||||||||||||||||||||||
Acquired intangible assets amortization | 5.1 | 0.7 | % | 0.03 | 0.03 | 5.2 | 0.6 | % | 0.03 | 0.03 | 5.5 | 0.7 | % | 0.03 | 0.03 | |||||||||||||||||||||||||||||||||
Loss on convertible debt conversions (2) | - | - | - | - | 3.4 | 0.4 | % | 0.02 | 0.02 | 4.1 | 0.5 | % | 0.02 | 0.02 | ||||||||||||||||||||||||||||||||||
Interest and other (2) | - | - | - | - | 1.2 | 0.1 | % | 0.01 | 0.01 | 3.6 | 0.5 | % | 0.02 | 0.02 | ||||||||||||||||||||||||||||||||||
Pension mark-to-market adjustment (2) | - | - | - | - | (1.6 | ) | -0.2 | % | (0.01 | ) | (0.01 | ) | - | - | - | - | ||||||||||||||||||||||||||||||||
Exclude discrete tax adjustments | (10.4 | ) | -1.4 | % | (0.06 | ) | (0.06 | ) | (6.5 | ) | -0.7 | % | (0.04 | ) | (0.04 | ) | (15.1 | ) | -1.9 | % | (0.09 | ) | (0.08 | ) | ||||||||||||||||||||||||
Non-GAAP tax adjustments | (3.3 | ) | -0.4 | % | (0.02 | ) | (0.02 | ) | (0.2 | ) | -0.0 | % | (0.00 | ) | (0.00 | ) | (0.3 | ) | -0.0 | % | (0.00 | ) | (0.00 | ) | ||||||||||||||||||||||||
Convertible share adjustment (3) | - | - | - | 0.01 | - | - | - | 0.03 | - | - | - | 0.06 | ||||||||||||||||||||||||||||||||||||
Net income - non-GAAP | $ | 169.0 | 22.4 | % | $ | 1.04 | $ | 0.98 | $ | 238.2 | 26.9 | % | $ | 1.46 | $ | 1.37 | $ | 196.2 | 25.1 | % | $ | 1.18 | $ | 1.11 | ||||||||||||||||||||||||
GAAP and non-GAAP weighted average common shares - basic | 162.0 | 162.8 | 166.5 | |||||||||||||||||||||||||||||||||||||||||||||
GAAP weighted average common shares - diluted | 175.6 | 178.0 | 187.7 | |||||||||||||||||||||||||||||||||||||||||||||
Exclude dilutive shares related to convertible note transaction | (2.5 | ) | (3.4 | ) | (10.3 | ) | ||||||||||||||||||||||||||||||||||||||||||
Non-GAAP weighted average common shares - diluted | 173.1 | 174.6 | 177.4 | |||||||||||||||||||||||||||||||||||||||||||||
(1 | ) | Restructuring and other consists of: | ||||||||||||||||||||||||||||||||||||||||||||||
Quarter Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
2022 | 2021 | 2021 | ||||||||||||||||||||||||||||||||||||||||||||||
Litigation Settlement | $ | 14.7 | $ | 12.0 | $ | - | ||||||||||||||||||||||||||||||||||||||||||
Employee severance | 0.6 | 0.3 | 0.2 | |||||||||||||||||||||||||||||||||||||||||||||
Acquisition related expenses and compensation | (0.2 | ) | 0.2 | (0.2 | ) | |||||||||||||||||||||||||||||||||||||||||||
Contingent consideration fair value adjustment | - | - | (7.2 | ) | ||||||||||||||||||||||||||||||||||||||||||||
Other | 0.7 | 0.3 | 0.1 | |||||||||||||||||||||||||||||||||||||||||||||
$ | 15.7 | $ | 12.7 | $ | (7.1 | ) | ||||||||||||||||||||||||||||||||||||||||||
(2 | ) | For the quarters ended | ||||||||||||||||||||||||||||||||||||||||||||||
(3 | ) | For the quarters ended | ||||||||||||||||||||||||||||||||||||||||||||||
GAAP to Non-GAAP Reconciliation of Second Quarter 2022 guidance: | ||||||||||||||||||||||||||||||||||||||||||||||||
GAAP and non-GAAP second quarter revenue guidance: | to | |||||||||||||||||||||||||||||||||||||||||||||||
GAAP net income per diluted share | $ | 0.96 | $ | 1.25 | ||||||||||||||||||||||||||||||||||||||||||||
Exclude acquired intangible assets amortization | 0.03 | 0.03 | ||||||||||||||||||||||||||||||||||||||||||||||
Convertible share adjustment | 0.01 | 0.01 | ||||||||||||||||||||||||||||||||||||||||||||||
Non-GAAP net income per diluted share | $ | 1.00 | $ | 1.29 | ||||||||||||||||||||||||||||||||||||||||||||
For press releases and other information of interest to investors, please visit Teradyne's homepage at http://www.teradyne.com. | ||||||||||||||||||||||||||||||||||||||||||||||||
Contact: | ||||||||||||||||||||||||||||||||||||||||||||||||
Andy Blanchard 978-370-2425 | ||||||||||||||||||||||||||||||||||||||||||||||||
Vice President of Corporate Relations |